A securities fraud lawsuit has been filed against ImmunityBio, Inc. and some of its executives, alleging they made false or misleading statements about the company's capabilities and business prospects. The suit claims that ImmunityBio's CEO overstated the capabilities of a product called Anktiva, which led to inflated stock prices and investor losses when the truth emerged. Investors who bought ImmunityBio stock between January 19 and March 24, 2026, and suffered losses may be eligible to join the lawsuit and seek recovery. The deadline to apply as lead plaintiff is May 26, 2026, and investors are encouraged to contact the law firm Block & Leviton for more information and assistance.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
